<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010383</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01902</org_study_id>
    <nct_id>NCT04010383</nct_id>
  </id_info>
  <brief_title>Non-inferiority Study for Visual Field Measurements Using a Virtual Reality Device</brief_title>
  <official_title>Non-inferiority Study for Visual Field Measurements Using a Virtual Reality Device on Participants With Normal and Glaucomatous Visual Fields</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that performing VF measurements with a Virtual Reality headset using
      similar testing strategies as implemented in conventional perimeters, allow for a
      non-inferior quality in VF acquisitions. The results of this study will show if valid
      measurements of such devices in human subjects can be obtained.

      The primary endpoint of this study is the non-inferiority estimation quality of participant's
      mean defect (MD) measured in decibel (dB) between the head-mounted display and an OCTOPUS
      perimeter using the dynamic strategy (DS) for participants with normal or glaucomatous visual
      field. The MD is a clinical measure for the average loss of visual function calculated from
      the visual field of a participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>non-inferiority estimation quality of mean defect (MD) measured in decibels (dB) between the virtual reality perimeter and the OCTOPUS 900 perimeter</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary endpoint of this study is the non-inferiority estimation quality of participant's mean defect (MD) measured in decibel (dB) between the head-mounted display and an OCTOPUS perimeter using the dynamic strategy (DS) for participants with normal or glaucomatous visual field. The MD is a clinical measure for the average loss of visual function calculated from the visual field of a participant.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Visual Field Tests</condition>
  <arm_group>
    <arm_group_label>normal visual field subjects</arm_group_label>
    <description>Cataract yes or no
Age range 40 - 80 years
normal visual field (MD: &lt; +2 dB)
Refractive error within ±5 dpt. spherical equivalent
Astigmatism of &lt; -3 dpt.
Visual acuity of ≥0.3 logMar (decimal ≥0.5)
Experience in perimetry (history of at least one perimetry examination)
False positive or negative errors each less than 20% in each examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucomatous subjects</arm_group_label>
    <description>Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma
Early to moderate visual field loss (MD: +2 to +12 dB)
Refractive error within ±5 dpt. spherical equivalent
Astigmatism of &lt; -3 dpt.
Visual acuity of ≥0.3 logMar (decimal ≥0.5)
Experience in perimetry (history of at least one perimetry examination)
False positive or negative errors each less than 20% in each examination
Cataract yes or no
Age range 40 - 80 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>virtual reality perimeter</intervention_name>
    <description>Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.</description>
    <arm_group_label>Glaucomatous subjects</arm_group_label>
    <arm_group_label>normal visual field subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of glaucoma patients and patients with normal visual fields
        respecting the inclusion/exclusion criteria. There is no restriction in ethnicity.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Written informed consent

        Inclusion Criteria for normal visual field subjects:

          -  Cataract yes or no

          -  Age range 40 - 80 years- normal visual field (MD: &lt; +2 dB)

          -  Refractive error within ±5 dpt. spherical equivalent

          -  Astigmatism of &lt; -3 dpt.

          -  Visual acuity of ≥0.3 logMar (decimal ≥0.5)

          -  Experience in perimetry (history of at least one perimetry examination)

          -  False positive or negative errors each less than 20% in each examination

        Inclusion Criteria for glaucomatous subjects:

          -  Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma

          -  Early to moderate visual field loss (MD: +2 to +12 dB)

          -  Refractive error within ±5 dpt. spherical equivalent

          -  Astigmatism of &lt; -3 dpt.

          -  Visual acuity of ≥0.3 logMar (decimal ≥0.5)

          -  Experience in perimetry (history of at least one perimetry examination)

          -  False positive or negative errors each less than 20% in each examination

          -  Cataract yes or no

        Exclusion Criteria:

          -  Exclusion criteria are subjects younger than 40 and older than 80 years

          -  Inability to follow the procedure

          -  Insufficient knowledge of project language

          -  The history of other ocular diseases than glaucoma or cataract or other conditions
             that might affect visual field testing (e.g. pituitary lesions, demyelinating
             diseases).

          -  Any history of epilepsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René G Höhn, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University Hospital Bern, Berne, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>René G Höhn, Dr. med.</last_name>
    <phone>+41 31 63 22501</phone>
    <email>rene.hoehn@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bern, Department of Ophthalmology</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>René G Höhn, Dr. med.</last_name>
      <phone>0041316329717</phone>
      <email>rene.hoehn@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perimetry</keyword>
  <keyword>Virtual reality device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

